Trial Information

Summary: Diabetic Peripheral Neuropathy (DPN)

20 week, DPN study designed to evaluate the dose response of the new PRODRUG of Gabapentin (Neurontin)compared to Lyrica (Pregablin)and placebo in subjects with DPN. There are 10 clinic visits and patients will be compensated for their time and travel upon completion of study.

Patient Inclusion Criteria:

• Male or female age 18 or older
• History of pain for at least six months no greater than 5 years atributed to DPN, must have lower extremity pain
• Pain of 4 or greater most days on scale of 1 to 10
• Type I or II with no changes in diabetic medications for 3 months
• HbA1c must be 11 or less

Patient Exclusion Criteria:

• Chronic Hepatitis B or C
• Active epilepsy or any active seizure disorder requiring antiepileptic drugs
• Active significant psychiatric disorders in the last year requiring treatment except SSRIs
• Participated in a clinical study with investigational drug within 6 months
• Allergic reaction, or adverse reaction to: Gabapentin, Pregablin, or Acetaminophen

If you would like to learn more about participating in this study, please send an e-mail message using the form below.